An open, parallel group study comparing a frusemide/amiloride diuretic and a diuretic containing cyclopenthiazide with sustained release potassium in the treatment of congestive cardiac failure--a multicentre general practice study.
A total of 71 patients with cardiac failure requiring diuretic treatment were randomly allocated to receive either 20 mg frusemide/2.5 mg amiloride or 0.25 mg cyclopenthiazide/8.1 mmol sustained release potassium once daily for 12 weeks. Of the 35 patients treated with cyclopenthiazide/potassium, in 47% of patients the daily dose was doubled compared with in only 30% of the 36 patients treated with frusemide/amiloride. Both treatments significantly improved crepitations, oedema, orthopnoea and patient self-assessments of dyspnoea on effort; there were no significant differences between the two treatments. Plasma potassium concentrations were unaffected by either treatment and there were no clinically significant changes in laboratory data. Of the five patients receiving frusemide/amiloride and of the eight receiving cyclopenthiazide/potassium who withdrew from the trial, three and four, respectively, were due to possible drug-related effects. It is concluded that frusemide/amiloride is efficacious and acceptable for the treatment of congestive heart failure.
Allman
S
S
Rorer Health Care Ltd, Eastbourne, East Sussex, UK.
Norris
R J
RJ
D000368:Aged; D000584:Amiloride / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003518:Cyclopenthiazide / Q000009:adverse effects / Q000627:therapeutic use*; D003692:Delayed-Action Preparations; D004232:Diuretics; D004338:Drug Combinations / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D005665:Furosemide / Q000009:adverse effects / Q000627:therapeutic use*; D006333:Heart Failure / Q000188:drug therapy* / Q000503:physiopathology; D006339:Heart Rate; D006801:Humans; D008297:Male; D015337:Multicenter Studies as Topic; D011188:Potassium / Q000009:adverse effects / Q000627:therapeutic use*; D049993:Sodium Chloride Symporter Inhibitors / Q000627:therapeutic use*
D003692:Delayed-Action Preparations; D004232:Diuretics; D004338:Drug Combinations; D049993:Sodium Chloride Symporter Inhibitors; D000584:Amiloride; D005665:Furosemide; C046878:frumil; D011188:Potassium; D003518:Cyclopenthiazide